Globenewswireยท2025-06-25 05:00Core Viewpoint - Novartis has successfully completed a tender offer to acquire Regulus Therapeutics, with approximately 74.49% of the outstanding shares validly tendered [2] Group 1: Acquisition Details - Novartis offered $7.00 in cash per share plus one contingent value right (CVR) for each share, which represents a potential additional payment of $7.00 upon achieving a regulatory milestone [1] - The tender offer expired on June 24, 2025, at 11:59 p.m. New York City Time [1] - The transaction is expected to close on June 25, 2025, following the acceptance of all validly tendered shares [2] Group 2: Shareholder Participation - A total of approximately 56,374,397 shares were validly tendered, indicating strong shareholder support for the acquisition [2]